PREDNISONE 2.5 mg Tablet, 21-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- Prednisone calms down your immune system and reduces inflammation in your body. It's used for a huge range of conditions — everything from asthma and severe allergies to Crohn's di...
- Why did my doctor put me on prednisone — what does it actually do?
- Yes, morning really does matter — your body naturally produces its own cortisol hormone between 2 a.m. and 8 a.m., and taking prednisone at that time works with your body's rhythm...
- Do I really have to take it in the morning? And does it matter if I take it with food?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Prednisone — tap one for details:
Prednisone may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII CQ3XH3DET6
D&C Yellow No. 10 Aluminum Lake is a yellow colorant made by combining a dye with aluminum salts. It's used in medicines to add color for product identification and visual appeal.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII 5856J3G2A2
A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
6 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.2837 | $5.96 / 21 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| PredniSONE 2.5 mg 00054-4742-25 | Hikma | 100 tablets | $0.068 | AB | Availability likely | — |
| Prednisone 2.5 mg 00603-5336-21 | Par | 100 tablets | $0.068 | AB | Availability likely | — |
| Prednisone 2.5 mg 59651-0485-01 | Aurobindo | 100 tablets | $0.068 | AB | Availability likely | — |
| Prednisone 2.5 mg 70954-0057-10 | ANI | 100 tablets | $0.068 | AB | Availability likely | — |
| PredniSONE 2.5 mg 00054-8740-25 | Hikma | 100 tablets | $0.082 | AB | FDA listed | — |
| Prednisone 2.5 mg 10135-0775-01 | Marlex | 100 tablets | — | AB | FDA listed | — |
| prednisone 2.5 mg 50090-7235-00 | A-S | 30 tablets | — | — | FDA listed | — |
| Prednisone 2.5 mg 50090-7825-00 | A-S | 30 tablets | — | AB | FDA listed | — |
| Prednisone 2.5 mg 51655-0197-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| PredniSONE 2.5 mg 51655-0763-52 | Northwind | 30 tablets | — | — | FDA listed | — |
| Prednisone 2.5 mg 63629-2260-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| prednisone 2.5 mg 64380-0835-01 | Strides | 100 tablets | — | AB | FDA listed | — |
| Prednisone 2.5 mg 67046-1448-03 | Coupler | 30 tablets | — | AB | FDA listed | — |
| prednisone 2.5 mg 68788-8184-03 | Preferred | 30 tablets | — | — | FDA listed | — |
| Prednisone 2.5 mg 68788-8858-01 | Preferred | 15 tablets | — | AB | FDA listed | — |
| prednisone 2.5 mg 71335-2088-01 | Bryant | 30 tablets | — | — | FDA listed | — |
| Prednisone 2.5 mg 71335-2356-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Prednisone 2.5 mgthis 87063-0042-21 | ASCLEMED | 21 tablets | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 87063-0042-01 | 100 TABLET in 1 BOTTLE (87063-042-01) | 2025-12-03 | Active |
| 87063-0042-18 | 18 TABLET in 1 BOTTLE (87063-042-18) | 2025-12-03 | Active |
| 87063-0042-20 | 20 TABLET in 1 BOTTLE (87063-042-20) | 2025-12-03 | Active |
| 87063-0042-21 You're viewing this | 21 TABLET in 1 BOTTLE (87063-042-21) | 2025-12-03 | Active |
| 87063-0042-30 | 30 TABLET in 1 BOTTLE (87063-042-30) | 2025-12-03 | Active |
| 87063-0042-60 | 60 TABLET in 1 BOTTLE (87063-042-60) | 2025-12-03 | Active |
| 87063-0042-78 | 10 BLISTER PACK in 1 CARTON (87063-042-78) / 10 TABLET in 1 BLISTER PACK | 2025-12-03 | Active |
| 87063-0042-90 | 90 TABLET in 1 BOTTLE (87063-042-90) | 2025-12-03 | Active |
Pack size FAQ
What quantity is in NDC 87063-0042-21?
What is the difference between NDC 87063-0042-21 and NDC 87063-0042-18?
What NDC number is used to bill for this package of PREDNISONE 2.5 mg Tablet?
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Does this product come in other package sizes?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Prednisone tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis.
Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION The initial dosage of prednisone may vary from 5 mg to 60 mg prednisone per day, depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice, while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted.
If after a reasonable period of time there is a lack of satisfactory clinical response, prednisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.
It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation, it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient’s condition.
If after long-term therapy the drug is to be stopped it is recommended that it be withdrawn gradually rather than abruptly. Multiple Sclerosis In the treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective. (Dosage range is the same for prednisone and prednisolone.) Alternate Day Therapy Alternate day therapy is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning.
The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children. The rationale for this treatment schedule is based on two major premises: (a) the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for re-establishment of more nearly normal hypothalamic-pituitary-adrenal (HPA) activity on the off-steroid day.
A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm.
Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenocortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenocortical activity.
There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight. The diurnal rhythm of the HPA axis is lost in Cushing’s disease, a syndrome of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadrenocorticism may be noted…
⛔ Contraindications ▾
CONTRAINDICATIONS Prednisone tablets are contraindicated in systemic fungal infections and known hypersensitivity to components.
⚠️ Warnings ▾
WARNINGS In patients on corticosteroid therapy subject to any unusual stress, increased dosage of rapidly acting corticosteroids before, during and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including prednisone, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal.
The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider prednisone withdrawal or dosage reduction as needed. Tuberculosis If prednisone is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur.
Closely monitor such patients for reactivation. During prolonged prednisone therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including prednisone.
In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: If a prednisone-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. If a prednisone-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.
Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including prednisone. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with prednisone.
For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy. Fungal Infections Corticosteroids, including prednisone, may exacerbate systemic fungal infections; therefore, avoid prednisone use in the presence of such infections unless prednisone is needed to control drug reactions. For patients on chronic prednisone therapy who develop systemic fungal infections, prednisone withdrawal or dosage reduction is recommended.
Amebiasis Corticosteroids, including prednisone, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating prednisone in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteroids, including prednisone, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation.
In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Cerebral Malaria Avoid corticosteroids, including prednisone, in patients with cerebral malaria. Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions.
Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma. Prolonged use of corticosteroids m…
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Fluid and Electrolyte Disturbances Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Dermatologic Impaired wound healing Thin fragile skin Petechiae and ecchymoses Facial erythema Increased sweating May suppress reactions to skin tests Metabolic Negative nitrogen balance due to protein catabolism Neurological Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment Convulsions Vertigo Headache Endocrine Menstrual irregularities Development of Cushingoid state Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness Suppression of growth in children Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Ophthalmic Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos Addit i onal React i ons Urticaria and other allergic, anaphylactic or hypersensitivity reactions
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Prednisone Tablets USP, 2.5 mg are yellow colored, round, biconvex tablets, scored on one side and “PE”, “11” on other side. They are supplied as follows: Bottles of 18 NDC 87063-042-18 (repackaged from NDC 59651-485-XX) Bottles of 20 NDC 87063-042-20 (repackaged from NDC 59651-485-XX) Bottles of 21 NDC 87063-042-21 (repackaged from NDC 59651-485-XX) Bottles of 30 NDC 87063-042-30 (repackaged from NDC 59651-485-XX) Bottles of 60 NDC 87063-042-60 (repackaged from NDC 59651-485-XX) Bottles of 90 NDC 87063-042-90 (repackaged from NDC 59651-485-XX) Bottles of 100 NDC 87063-042-01 (relabeled from NDC 59651-485-01) 10x10 Unit-dose Tablets NDC 87063-042-78 (relabeled from NDC 59651-485-78) Prednisone Tablets USP, 5 mg are orange colored, round, biconvex tablets, scored on one side and “PI”, “5” on other side.
They are supplied as follows: Bottles of 18 NDC 87063-043-18 (repackaged from NDC 59651-486-XX) Bottles of 20 NDC 87063-043-20 (repackaged from NDC 59651-486-XX) Bottles of 21 NDC 87063-043-21 (repackaged from NDC 59651-486-XX) Bottles of 30 NDC 87063-043-30 (repackaged from NDC 59651-486-XX) Bottles of 60 NDC 87063-043-60 (repackaged from NDC 59651-486-XX) Bottles of 90 NDC 87063-043-90 (repackaged from NDC 59651-486-XX) Bottles of 100 NDC 87063-043-01 (relabeled from NDC 59651-486-01) 10x10 Unit-dose Tablets NDC 87063-043-78 (relabeled from NDC 59651-486-78) Prednisone Tablets USP, 10 mg are white to off-white, round, biconvex tablets, scored on one side and “PI”, “10” on other side.
They are supplied as follows: Bottles of 18 NDC 87063-044-18 (repackaged from NDC 59651-487-XX) Bottles of 20 NDC 87063-044-20 (repackaged from NDC 59651-487-XX) Bottles of 21 NDC 87063-044-21 (repackaged from NDC 59651-487-XX) Bottles of 30 NDC 87063-044-30 (repackaged from NDC 59651-487-XX) Bottles of 60 NDC 87063-044-60 (repackaged from NDC 59651-487-XX) Bottles of 90 NDC 87063-044-90 (repackaged from NDC 59651-487-XX) Bottles of 100 NDC 87063-044-01 (relabeled from NDC 59651-487-01) 10x10 Unit-dose Tablets NDC 87063-044-78 (relabeled from NDC 59651-487-78) Prednisone Tablets USP, 20 mg are white to off-white, round, biconvex tablets, scored on one side and “PI”, “20” on other side.
They are supplied as follows: Bottles of 18 NDC 87063-045-18 (repackaged from NDC 59651-488-XX) Bottles of 20 NDC 87063-045-20 (repackaged from NDC 59651-488-XX) Bottles of 21 NDC 87063-045-21 (repackaged from NDC 59651-488-XX) Bottles of 30 NDC 87063-045-30 (repackaged from NDC 59651-488-XX) Bottles of 60 NDC 87063-045-60 (repackaged from NDC 59651-488-XX) Bottles of 90 NDC 87063-045-90 (repackaged from NDC 59651-488-XX) Bottles of 100 NDC 87063-045-01 (relabeled from NDC 59651-488-01) 10x10 Unit-dose Tablets NDC 87063-045-78 (relabeled from NDC 59651-488-78) Prednisone Tablets USP, 50 mg are white to off-white, round, biconvex tablets, scored on one side and “PI”, “50” on other side.
They are supplied as follows: Bottles of 18 NDC 87063-048-18 (repackaged from NDC 59651-489-XX) Bottles of 20 NDC 87063-048-20 (repackaged from NDC 59651-489-XX) Bottles of 21 NDC 87063-048-21 (repackaged from NDC 59651-489-XX) Bottles of 30 NDC 87063-048-30 (repackaged from NDC 59651-489-XX) Bottles of 60 NDC 87063-048-60 (repackaged from NDC 59651-489-XX) Bottles of 90 NDC 87063-048-90 (repackaged from NDC 59651-489-XX) Bottles of 100 NDC 87063-048-01 (relabeled from NDC 59651-489-01) 10x10 Unit-dose Tablets NDC 87063-048-78 (relabeled from NDC 59651-489-78) Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Dispense in a tight, child-resistant container as defined in the USP/NF. PROTECT FROM MOISTURE. Relabeled and Repackaged by: Enovachem PHARMACEUTICALS Torrance, CA 90501
📋 Description ▾
DESCRIPTION Prednisone tablets, USP are available for oral administration containing either 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone USP. Each tablet contains the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch (maize), and sodium starch glycolate. In addition, 2.5 mg contains D&C yellow No.10 aluminum lake and 5 mg contains FD&C yellow # 6 aluminum lake.
Prednisone tablets, USP contain prednisone USP which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. The chemical name for prednisone is 17,21-dihydroxypregna-1,4-dienne-3,11,20-trione.
The structural formula is represented below: C 21 H 26 O 5 M.W. 358.44 Prednisone USP is a white to partially white, odorless crystalline powder. It is very slightly soluble in water; slightly soluble in alcohol, chloroform, dioxane, and methanol.
FDA approved dissolution test specifications differ from USP. Chemical Structure
💬 Information for Patients ▾
Information for the Patient Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and, if exposed, to obtain medical advice.